ESMO 2025 – Novartis looks for Pluvicto prostate Addition
But the ESMO discussant recommends against widespread use in hormone-sensitive disease.
GenFleet broadens its RAS ambitions
And Treeline and HengRui also get in on the pan-RAS act.
ESMO 2025 preview – a bemarituzumab reckoning approaches
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
FDA red and green lights: March 2025
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
Novartis gets a PSMAfore green flag at last
Pre-chemo prostate cancer beckons, but Pluvicto has a long way to go to hit $5bn sales.
Xilio's second bailout
AbbVie follows Gilead in throwing Xilio a lifeline.
Novartis’s post-Pluvicto plan materialises
The company has two actinium-labelled PSMA radiopharmaceuticals, and one is about to pivotal.
